Esansiyel Trombositoz Tedavisi
Kaynaklar:
1-Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27. 332(17):1132-6.
2-Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7. 353(1):33-45.
3-Aruch D, Mascarenhas J. Contemporary approach to essential thrombocythemia and polycythemia vera. Curr Opin Hematol. 2016 Mar. 23 (2):150-60.
4-Kanakura Y, Shirasugi Y, Yamaguchi H, Koike M, Chou T, Okamoto S, et al. A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia. Int J Hematol. 2018 Nov. 108 (5):491-498.
5-Godfrey AL, Campbell PJ, MacLean C, et al. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. J Clin Oncol. 2018 Aug 28. JCO2018788414.
6-Tefferi A, Szuber N, Pardanani A, Hanson CA, Vannucchi AM, Barbui T, et al. Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. Am J Hematol. 2021 Jun 1. 96 (6):E182-E184.
7-Riley CH, Brimnes MK, Hansen M, Jensen MK, Hasselbalch HC, Kjaer L, et al. Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets and dendritic cells in patients with JAK2V617F -positive essential thrombocythemia and polycythemia vera. Eur J Haematol. 2015 Sep 19.
8-Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, et al. Clinical and molecular response to interferon alpha therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015 Oct 20.
9-[Guideline] Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004 Feb. 89 (2):215-32.
10-Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015 Feb. 90 (2):162-73.
11-Schrickel L, Heidel FH, Sadjadian P, Becker T, Kolatzki V, Hochhaus A, et al. Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety. J Cancer Res Clin Oncol. 2021 May. 147 (5):1481-1491.
12-Edahiro Y, Yasuda H, Gotoh A, Morishita S, Suzuki T, Takeda J, et al. Interferon therapy for pregnant patients with essential thrombocythemia in Japan. Int J Hematol. 2021 Jan. 113 (1):106-111.
13-Gangat N, Tefferi A. Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations. Am J Hematol. 2021 Mar 1. 96 (3):354-366.
14-Pieri L, Pancrazzi A, Pacilli A, Rabuzzi C, Rotunno G, Fanelli T, et al. JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood. 2015 May 21. 125 (21):3352-3.
15-Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017 Oct 26. 130 (17):1889-1897.
16-Nelson R. FDA Approves Fedratinib for the Treatment of Myelofibrosis. August 16, 2019; Accessed: August 16, 2019.
17-Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM, et al. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. N Engl J Med. 2015 Sep 3. 373 (10):908-19.
